Compared to COVID − 19 patients without headache, serum levels of HMGB1, NLRP3, IL-6, angiotensin II, and ACE2 were significantly higher in COVID-19 patients with severe headache (Figs. 1 and 2). This evidence concerns the gene HMGB1 and Headache.